SCHEMBL10276014

SCHEMBL10276014

Cc1nn2c(=O)cc(-c3ccc(N)cc3)[nH]c2c1-c1ccc(F)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.38
NR3C2 P08235 1/20 0.38
MAPK14 Q16539 2/20 0.37
GCGR P47871 1/20 0.37
KIT P10721 5/20 0.36
ADORA2A P29274 2/20 0.34
ADORA1 P30542 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 1/20 0.34
THRB P10828 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
BTK Q06187 1/20 0.33
BRD4 O60885 2/20 0.33
ADORA2B P29275 1/20 0.33
ARF6 P62330 1/20 0.33
PTGS2 P35354 1/20 0.33
PDE7A Q13946 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10276122 0.88 PLAT (0.40) PGRNR3C2GCGRSMN1; SMN2ARF6
SCHEMBL10276073 0.88 ALDH1A1 (0.44) PGRNR3C2MAPK14GCGRKIT
SCHEMBL10280465 0.87 GCGR (0.40) PGRNR3C2MAPK14GCGRKMT2A
SCHEMBL10313533 0.83 MEN1 (0.45) PGRNR3C2MAPK14GCGRMEN1
SCHEMBL10276103 0.82 PGR (0.37) PGRNR3C2MAPK14GCGRKIT
SCHEMBL10275579 0.80 MEN1 (0.37) PGRNR3C2MAPK14KITMEN1
SCHEMBL10275534 0.80 TNKS2 (0.40) PGRNR3C2MAPK14KITMEN1
SCHEMBL10275482 0.79 PLAT (0.40) PGRNR3C2MEN1KMT2AALDH1A1
SCHEMBL10275685 0.79 DHODH (0.39) PGRNR3C2MAPK14GCGRKIT
SCHEMBL17298709 0.78 MEN1 (0.43) MAPK14GCGRADORA2AADORA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
WO-2011035518-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF 辽宁利锋科技开发有限公司 (CN) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 PGR 3472/4885NR3C2 1731/4885MAPK14 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.